Acute drug prescribing to children on chronic antiepilepsy therapy and the potential for adverse drug interactions in primary care.

AIMS To investigate the extent of acute coprescribing in primary care to children on chronic antiepileptic therapy, which could give rise to potentially harmful drug-drug interactions. DESIGN Acute coprescribing to children on chronic antiepileptic drug therapy in primary care was assessed in 178 324 children aged 0-17 years for the year 1 November 1999 to 31 October 2000. Computerized prescribing data were retrieved from 161 representative general practices in Scotland. SETTING One hundred and sixty-one general practices throughout Scotland. RESULTS During the study year 723 (0.41%) children chronically prescribed antiepileptic therapy were identified. Fourteen antiepileptic agents were prescribed, with carbamazepine, sodium valproate and lamotrigine accounting for 80% of the total. During the year children on chronic antiepileptic therapy were prescribed 4895 acute coprescriptions for 269 different medicines. The average number of acute coprescriptions for non-epileptic drug therapy were eight, 11, six, and six for the 0-1, 2-4, 5-11, and 12-17-year-olds, respectively. Of these acute coprescriptions 72 (1.5%) prescribed to 22 (3.0%) children were identified as a potential source of clinically serious interactions. The age-adjusted prevalence rates for potentially serious coprescribing were 86, 26, 22, and 33/1000 children chronically prescribed antiepileptic therapy in the 0-1, 2-4, 5-11, and 12-17-year-old age groups, respectively. The drugs most commonly coprescribed which could give rise to such interactions were antacids, erythromycin, ciprofloxacin, theophylline and the low-dose oral contraceptive. For 10 (45.5%0 of the 20 children identified at risk of a potentially clinically serious adverse drug interaction, the acute coprescription was prescribed off label because of age or specific contraindication/warning. CONCLUSIONS In primary care, 3.0% of children on chronic antiepileptic therapy are coprescribed therapeutic agents, which could give rise to clinically serious drug-drug interactions.

[1]  J. McNamara.  Emerging insights into the genesis of epilepsy , 1999, Nature.

[2]  J. Cramer,et al.  Use of oral contraceptives by women with epilepsy. , 1986, JAMA.

[3]  J. Mclelland,et al.  PHENYTOIN/DEXAMETHASONE INTERACTION: A CLINICAL PROBLEM , 1978, The Lancet.

[4]  T. Pedley,et al.  Clinical pharmacology of antiepileptic drugs. , 2003, Clinical neuropharmacology.

[5]  I. Choonara,et al.  Surveillance for fatal suspected adverse drug reactions in the UK , 2002, Archives of disease in childhood.

[6]  H. Gebben,et al.  Drug use of children in the community assessed through pharmacy dispensing data. , 2000, British journal of clinical pharmacology.

[7]  N. Thrane,et al.  A one‐year population‐based study of drug prescriptions for Danish children , 1999, Acta paediatrica.

[8]  E. Tanaka.  Clinically significant pharmacokinetic drug interactions between antiepileptic drugs , 1999, Journal of clinical pharmacy and therapeutics.

[9]  A. Menotti,et al.  Role of body mass index in the prediction of all cause mortality in over 62,000 men and women. The Italian RIFLE Pooling Project. Risk Factor and Life Expectancy. , 1998, Journal of epidemiology and community health.

[10]  E. Perucca,et al.  Elevation of plasma carbamazepine concentrations by ketoconazole in patients with epilepsy. , 1997, Therapeutic drug monitoring.

[11]  E. Perucca,et al.  Clinical Significance of Pharmacokinetic Interactions Between Antiepileptic and Psychotropic Drugs , 2002, Epilepsia.

[12]  M. Jann,et al.  Increased carbamazepine plasma concentrations after fluoxetine coadministration , 1991, Clinical pharmacology and therapeutics.

[13]  M. Duchowny,et al.  Pharmacokinetic Considerations in the Treatment of Childhood Epilepsy , 2003, Paediatric drugs.

[14]  I. Osorio,et al.  Antiepileptic Drug Intoxication: Factors and Their Significance , 1991, Epilepsia.

[15]  J. Horn,et al.  Potentially Serious Drug Interactions Secondary to High‐Dose Diltiazem Used in the Treatment of Pulmonary Hypertension , 1993, Pharmacotherapy.

[16]  M. Levine,et al.  Differential effect of cimetidine on serum concentrations of carbamazepine and phenytoin , 1985, Neurology.

[17]  P. Patsalos,et al.  The Importance of Drug Interactions in Epilepsy Therapy , 2002, Epilepsia.

[18]  Garnett Wr,et al.  Effects of three antacids on the bioavailability of valproic acid. , 1982, Clinical pharmacy.

[19]  R. Milne,et al.  Audit of populations in general practice: the creation of a national resource for the study of morbidity in Scottish general practice. , 1998, Journal of epidemiology and community health.

[20]  C. Pandolfini,et al.  Drug prescribing in out-patient children in Southern Italy , 2001, European Journal of Clinical Pharmacology.

[21]  Martin Schoell,et al.  Diamondoids and oil are not forever , 1999, Nature.

[22]  M. D. Freedman,et al.  Clinically Significant Drug Interactions with the Oral Anticoagulants , 1994, Drug safety.

[23]  B. Bourgeois.  New antiepileptic drugs in children: which ones for which seizures? , 2000, Clinical neuropharmacology.

[24]  M. Lapeyre-Mestre,et al.  Adverse drug reactions and off-label drug use in paediatric outpatients. , 2002, British journal of clinical pharmacology.

[25]  H. Hachad,et al.  New Antiepileptic Drugs: Review on Drug Interactions , 2002, Therapeutic drug monitoring.

[26]  J. Hallas,et al.  Drug prescribing among Danish children: a population-based study , 2001, European Journal of Clinical Pharmacology.

[27]  E. Perucca.  Pharmacologic Advantages of Antiepileptic Drug Monotherapy , 1997 .

[28]  S. Conroy,et al.  Unlicensed and Off-Label Drug Use in Children , 2002, Drug safety.

[29]  G. Granneman,et al.  Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions , 1997, Clinical pharmacokinetics.

[30]  M. Contin,et al.  Pharmacokinetic Interactions Between Antiepileptic Drugs , 1996, Clinical pharmacokinetics.

[31]  I. Choonara,et al.  Adverse drug reactions in a paediatric intensive care unit , 1995, Acta paediatrica.

[32]  S. Al-Rajeh,et al.  Carbamazepine toxicity induced by concurrent erythromycin therapy. , 1985, Archives of neurology.